Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Athersys has a 1 year low of $0.01 and a 1 year high of $1.99. The stock has a market cap of $833,000.00, a price-to-earnings ratio of 0.00 and a beta of -0.90.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.